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Background: BCL-3 is an essential negative regulator of inflammation.
Results: A peptide derived from the ankyrin repeat 1 domain of BCL-3 has anti-inflammatory properties.
Conclusion:The interaction of a short region of BCL-3 with p50 has significant functional consequences on inflammatory gene
expression.
Significance:Mimicking BCL-3 function has therapeutic potential.
The NF-B transcriptional response is tightly regulated by a
number of processes including the phosphorylation, ubiquitina-
tion, and subsequent proteasomal degradation of NF-B sub-
units. The IB family protein BCL-3 stabilizes a NF-B p50
homodimerDNA complex through inhibition of p50 ubiquiti-
nation. This complex inhibits the binding of the transcription-
ally active NF-B subunits p65 and c-Rel on the promoters of
NF-B target genes and functions to suppress inflammatory
gene expression. We have previously shown that the direct
interaction between p50 and BCL-3 is required for BCL-3-me-
diated inhibition of pro-inflammatory gene expression. In this
study we have used immobilized peptide array technology to
define regions of BCl-3 that mediate interaction with p50
homodimers. Our data show that BCL-3 makes extensive con-
tacts with p50 homodimers and in particular with ankyrin
repeats (ANK) 1, 6, and 7, and the N-terminal region of Bcl-3.
Using these data we have designed a BCL-3 mimetic peptide
based on a region of the ANK1 of BCL-3 that interacts with p50
and shares low sequence similarity with other IB proteins.
When fused to a cargo carrying peptide sequence this BCL-3-
derived peptide, but not a mutated peptide, inhibited Toll-like
receptor-induced cytokine expression in vitro. The BCL-3
mimetic peptide was also effective in preventing inflammation
in vivo in the carrageenan-induced paw edema mouse model.
This study demonstrates that therapeutic strategies aimed at
mimicking the functional activity of BCL-3 may be effective in
the treatment of inflammatory disease.
The NF-B transcription factor is a critical factor for the
normal development and homeostasis of the immune system
and is essential for the inflammatory response (1). NF-B con-
trols the expression of hundreds of genes that encode pro-in-
flammatory effectors such as cytokines and chemokines, pro-
teins involved in antigen presentation, and regulators of cell
death and proliferation. Mice lacking specific NF-B subunits
or components of the NF-B activation pathway are immuno-
defective and fail to develop the appropriate immunity to infec-
tion and have aberrant inflammatory responses (2). NF-B is in
fact a family of five related factors: p65/RelA, c-Rel, RelB, p50,
and p52, all of which possess a Rel homology domain, which
mediates subunit dimerization andDNAbinding. Each subunit
is capable of homodimerization or heterodimerization to yield
a theoretical 15 possible dimers, although only 12 specific
dimers have so far been demonstrated to exist in cells (3). The
p50 and p52 subunits are generated from the limited protea-
somal processing of the larger precursor proteins p105 and
p100, respectively. Importantly both p50 and p52 lack a trans-
activation domain and when present as homodimers lack
intrinsic transactivation activity (4).
The primary point of control of NF-B transcriptional activ-
ity is the sequestration of NF-B dimers in the cytoplasm by
members of the IB family of regulatory proteins, of which
IB is the archetypal member. Upon receipt of a NF-B acti-
vating stimulus, the inhibitor of B kinase (IKK)3 complex,
composed of the kinases IKK and IKK, and the scaffold pro-
tein NEMO, phosphorylates IB, triggering its ubiquitination
and subsequent proteasomal degradation. Free NF-B dimers
then translocate to the nucleuswhere they bind cognate sites on
DNA to regulate the transcription of target genes (4). More
recently a number of studies have identified critical regulatory
mechanisms in the nucleus that control NF-B transcriptional
activity. Most prominent among these is the regulation of
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NF-B stability by the ubiquitin-proteasomal system (5). The
ubiquitination ofNF-B is triggered byDNAbinding and is also
regulated by phosphorylation (6, 7). Ubiquitin-mediated pro-
teasomal degradation of theNF-B subunit p65/RelA is amajor
limiting factor in the transcription of target genes (7).
The stability of one NF-B dimer can also profoundly affect
the transcriptional activity of other NF-B dimers. The IB
protein BCL-3 inhibits the ubiquitination and subsequent pro-
teasomal degradation of p50 homodimers to limit the expres-
sion of pro-inflammatory cytokines following activation of
Toll-like receptors (8). BCL-3 is an atypical IB protein that, in
contrast to IB, is predominantly nuclear in localization and is
not degraded following activation of the IKK complex (8). BCL-
3-stabilized p50 homodimers form a stable repressor complex
at NF-B binding sites that competes with transcriptionally
active NF-B dimers composed of p65 or c-Rel to inhibit target
gene expression. BCL-3 is important for establishing TLR tol-
erance, a state of altered responsiveness to Toll-like receptor
stimulation in macrophage characterized by a block in pro-
inflammatory cytokine expression (8). Mice deficient in Bcl3
lack Toll-like receptor tolerance (8), fail to clear infection (9),
are more sensitive to the development of type I diabetes (10),
and undergo increased granulopoiesis under inflammatory
conditions (11). More recently BCL-3 has been identified as an
important enforcer of T cell differentiation states (12) and a key
factor in promoting dendritic cell priming of T cells (13). Thus
BCL-3 is an important regulator of inflammation and immune
responses.
We recently employed peptide array techniques to identify
critical amino acids of p50, which mediate the interaction with
BCL-3 (14). In this study we employ similar techniques to iden-
tify residues of BCL-3, which mediate interaction with p50.
This approach confirmed previously indicated sites of interac-
tion from in silicomodeling studies (15, 16) but also identified
additional sites of interaction not predicted by computational
methods. Our findings also provide important information on
the recognition of NF-B dimers by IB proteins. We used the
results of our peptide array analysis to generate a short peptide
of BCL-3, which mimicked the inhibitory effect of full-length
BCL-3 on NF-B in vitro. Moreover, the BCL-3 mimetic pep-
tide significantly inhibited carrageenan-induced paw inflam-
mation inmice.Our study demonstrates thatmimicking BCL-3
function may represent an effective strategy for the inhibition
of inflammation.
Experimental Procedures
Cell Culture, Plasmids, and Transfection—HEK293T, RAW
264.7, and HeLa cells were cultured in DMEM containing 10%
fetal bovine serum, 2 mM glutamine, and 100 units/ml of peni-
cillin/streptomycin. Transfections were performed using the in
vitro transfection reagent Turbofect according to the manu-
facturer’s instructions. Mammalian expression vectors for
BCL-3 and p50 were as previously described (8). p50 was sub-
cloned into the pGEX6p1 vector to produce a bacterial GST-
p50 expression vector.
Spot Synthesis of Peptides andOverlay Analysis—BCL-3 pep-
tide arrays were generated by automatic SPOT synthesis as pre-
viously described (17). Essentially, a library of overlapping pep-
tides each shifted by 4 amino acids, encompassing the entire
murine BCL-3 protein sequence was synthesized onWhatman
50 cellulose supports, using Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) chemistry and the AutoSpot-Robot ASS 222 (Intavis
Bioanalytical Instruments). BCL-3 peptide arrays were acti-
vated by incubation in 100% ethanol for 5 min followed by
equilibration in TBS-T for 10 min. Arrays were blocked in a 5%
nonfat milk/TBS, 0.05% Tween 20 solution for 1 h at room
temperature. To investigate the interaction of GST orGST-p50
with the BCL-3 peptides, arrays were incubated overnight with
10 g/ml of recombinant protein in a 1% nonfat milk/TBS-T
solution. Bound protein was detected by immunoblotting with
anti-GST and a secondary anti-rabbit antibody coupled with
horseradish peroxidase.
Recombinant Protein Expression and Purification—For puri-
fication of GST andGST-p50, Escherichia coliBL21CodonPlus
(Stratagene) were transformed with pGEX-6p1 or pGEX-6p1-
p50. Bacteria were incubated in 700 ml of LB at 37 °C with
agitation (220–240 rpm) until an A600 of 1.0–2.0 was reached
before inductionwith 1.0mM isopropyl 3-D-thiogalactopyrano-
side. Bacteria were grown for a further 16 h at 20 °C with agita-
tion (220–240 rpm) to induceGSTprotein expression. Bacteria
were pelleted at 4 °C and pellets were frozen at 20 °C to aid
lysis. Pellets were thawed on ice and resuspended in 70 ml of
cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM
dithiothreitol) supplemented with two complete, mini, EDTA-
free protease inhibitor mixture tablets (Roche Applied Sci-
ence). Pellets were disrupted by sonication on ice for 30 min
with 5-min pulses and 5 min rest between each pulse. Lysates
were cleared by centrifugation at 15,000 g for 30 min at 4 °C.
Recombinant proteins were affinity purified at 4 °C against
GSH-agarose (Sigma), following a 1-h incubation with the
cleared lysate, GSH-agarose was washed with 2 liters of wash
buffer (pH 7.5) overnight at 4 °C and recombinant proteins
were eluted with 10mM glutathione in 50mMTris (pH 8.5) and
150 mM NaCl.
GSTPulldownAssay—HEK293Tcellswere transiently trans-
fected with FLAG-BCL-3. Whole cell extracts were prepared
from cells resuspended in GST lysis and binding buffer (20 mM
Tris-Cl, pH 8.0, 200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5% Non-
idet P-40) supplemented with 2 g/ml of aprotinin, 1 g/ml of
pepstatin, and 1 mM PMSF. Equal concentrations of lysates
were precleared in 1 ml of binding buffer with 50 l of GSH-
agarose for 2 h rotating at 4 °C. GST or GST-p50 were incu-
bated with precleared lysates and affinity purified with 50 l of
GSH-agarose for 2 h rotating at 4 °C. Following three washes in
1 ml of binding buffer, pulldown complexes were eluted from
the GSH-agarose by boiling at 95 °C in 2 SDS gel loading
buffer (100 mM Tris-Cl, pH 6.8, 4%(w/v) SDS, 0.2% (w/v) bro-
mphenol blue, 20%(w/v) glycerol, and 200 mM -mercaptoeth-
anol) and analyzed byWestern blot. Anti-FLAGM2, anti-GST,
and anti--actin were purchased from Sigma.
BCL-3 Peptide Synthesis—The sequences of the Bcl-3
mimetic peptides were as follows: BDP1, YGRKKRRQRRHIA-
VVQNNIAAVYRILSLFKLGSREVDVHN; BDP2, YGRKKRR-
QRRAAVYRILSLFKLGSR; mBDP2, YGRKKRRQRRWAWG-
YILSLDCLGSY. BDP1 with an N-terminal FITC label was
Bcl-3Mimetic Peptide
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synthesized by GL Biochem Ltd. Shangai, BDP2 and mBDP2
were synthesized by Genscript.
Luciferase Assay—RAW 264.7 cells were transiently trans-
fected using Attractene (Qiagen) with an IL23p19 promoter
reporter plasmid and the Renilla luciferase expression vector
pRL-TK (Promega) for 24 h and cultured with or without 100
ng/ml of LPS (Sigma) for an additional 8 h as previously
described (16). Cells were lysed in 1 passive lysis buffer (Pro-
mega) and for all samples the firefly luciferase activity (25 mM
glycylglycine, 15 mM potassium diphosphate/K2PO4, pH 8, 4
mM EDTA, 15 mM magnesium sulfate, 75 M luciferin, 1 mM
dithiothreitol, 0.1 mM coenzyme A, 2 mM ATP) was divided by
that of the Renilla luciferase activity (1.1 M sodium chloride, 2.2
mM EDTA, 220 mM dipotassium phosphate/K2PO4, pH 5.1,
0.44 mg/ml of bovine serum albumin, 1.3 mM sodium azide,
1.43 M coelentrerazine) to normalize for the transfection effi-
ciency as previously described (18).
ELISA—5  104 RAW 264.7 cells were plated per well of a
96-well plate overnight. Cells were pretreated with peptide 2 h
before stimulation with 100 ng/ml of LPS and supernatants
were harvested after 4 h. The concentration of soluble TNF-
(pg/ml) in the culturemediumwas determinedusing themouse
TNF (Mono/Mono) ELISA set (BD Biosciences) and tetra-
methylbenzidine was purchased from Thermo Fisher.
Gene ExpressionAnalysis—For real-timePCR, total RNAwas
isolated using RNeasy kits (Qiagen) and reverse transcribed
using the NanoScript reverse transcription kit (Primer Design).
Real-time PCR was performed with SYBR Green SuperMix
with ROX (PerfeCTa) using QuantiTect Primer Assays (Qia-
gen). Data were normalized to 18S rRNA and gene expression
changes calculated using the 2CT method.
WST-1 Cell Viability Assay—5  104 RAW 264.7 cells were
plated per well in an opaque walled 96-well plate overnight.
Cells were treated with increasing concentrations of peptide
(0–100 M) for 6 h and viability was determined using cell
proliferation reagent WST-1 (Roche Applied Science) accord-
ing to the manufacturer’s instructions. The absorbance of the
sample wasmeasured at 450 nmwith a reference wavelength of
630 nm.
Multiple Sequence Alignment—Multiple sequence alignment
and similarity analysis was performed using AlignX software
(Vector NTI, Invitrogen) using the BLOSUM62 residue substi-
tution matrix. Similarity index of the ankyrin repeat domain
of the murine IB family was determined following align-
ment and expressed as a value of 0–1. Residues were scored
based on the similarity valuewhere 1 identical residues, 0.5
similar residues, and 0.2  weakly similar residues. The sum
value at each residue was then divided by the total number of
the sequences in the alignment. The BCL-3 crystal structure,
PDB ID 1K1B was annotated using 3D Molecule Viewer (Vec-
tor NTI, Invitrogen).
Mice and Carrageenan-induced Paw Edema—Male ICR
mice (Harlan), weighing 35–40 g,were used.Animalswere pro-
vided with food and water ad libitum and maintained on a
12/12-h light/dark cycle. All the procedures were performed in
accordance with local ethical and UK Home Office regulations
or with Italian and European regulations on protection of ani-
mals used for experimental and other scientific purposes. Paw
edema was induced by subplantar injection of 50 l of sterile
saline containing 2% -carrageenan (Sigma) into the right hind
paw (19). Paw volumes or thickness were measured by a
plethysmometer (Ugo Basile) or a dial caliper (Kroeplin
GmbH), respectively, at varying time intervals. The increase in
paw volume/thickness was evaluated as the difference between
the paw volume/thickness measured at each time point and the
basal paw volume/thickness measured immediately before car-
rageenan injection. The test agents used in this study, BCL-3-
derived peptide 2 (BDP2; 0.1, 1, and 10 mg/kg), mutated BDP2
(mBDP2; 10 mg/kg), and dexamethasone (Dex; 1 mg/kg),
were administered intraperitoneally 1 h before the induction
of the edema. The control group received an injection of PBS
intraperitoneally.
Flow Cytometry and Fluorescence Microscopy—Flow cytom-
etry of FITC-peptide-treated cells was performed using a BD
Bioscience FACScan. Data were analyzed using FlowJo soft-
ware. Fluorescence microscopy was performed using a Nikon
Digital Sight DS Fi1C camera and NIS element software
(Nikon).
Results
Analysis of BCL-3/p50 Binding by Peptide Array—Previous
models of BCL-3 and p50 homodimer interaction have relied
on the independently resolved crystal structures of BCL-3 and
p50homodimers (15, 20). These structures donot represent the
entire BCL-3 and p50 protein sequences and so these models
lack information on the C- andN-terminal regions of both pro-
teins.We recently employed a peptide array based technique to
identify amino acids of p50 that mediate interaction with
BCL-3 (14). Here, we took a similar approach to identify amino
acids of BCL-3 that mediate interaction with p50 homodimers.
A library of overlapping peptides 18 amino acids in length, each
shifted by 4 amino acids and encompassing the entire sequence
of BCL-3, was Spot-synthesized on a cellulose membrane to
generate a BCL-3 peptide array. Arrays were probedwith either
recombinant GST as a control or recombinant GST-p50 and
interaction was detected by immunoblotting with anti-GST
antibody. GST pulldown experiments demonstrated that GST-
p50 but not GST bound to BCL-3 (Fig. 1B). The peptide array
analysis revealed that GST-p50 bound specifically and strongly
to a number of peptides representing the N terminus and the
ANK1, -6, and -7 of BCL-3 (Fig. 1, C and D).
To identify amino acids within the identified peptides that
are required for binding to p50, a series of alanine scanning
arrays were generated. Arrays were derived from a p50 binding
18-mer parent peptide of interest and 18 new peptides contain-
ing a single successive alanine substitution were generated.
Where an alaninewas present on the parental peptide an aspar-
tate was substituted instead. Peptides selected represented the
BCL-3 N terminus region (aa 1–30), and ANK-1 (aa 138–160),
-6 (aa 297–330), and -7 (aa 330–362). As before, the alanine
scanning peptide arrays were incubated with GST-p50 prior to
immunoblotting with anti-GST antibody. Detection of GST-
p50 binding was then performed using near infrared IR dye-
conjugated secondary antibody to facilitate quantification of
GST-p50 binding to specific peptides using an infrared scanner.
The binding of GST-p50 to the substituted peptide was calcu-
Bcl-3Mimetic Peptide
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lated and expressed as a percentage binding of the control par-
ent peptide contained on the same array (supplemental Table
S1).We employed a cut-off of 40% reduction in binding relative
to the parental control peptide to identify individual amino
acids of BCL-3 that interact with p50 (Fig. 2).
Comparison of Peptide Array and in Silico Analysis of BCL-
3/p50 Interaction—The current in silico models of the BCL-
3p50 homodimer complex have relied on the partial crystal
structures of BCL-3, p50 homodimers, and the IBp65p50
complex (15, 20). We therefore compared the p50 interacting
amino acids of BCL-3 identified in our experiments with those
predicted by the studies of Michel et al. (20) and Manavalan et
al. (15). To do this, the murine and human BCL-3 protein
sequences were aligned to allow comparison of the potential
interacting amino acids determined by the peptide array data
(murine) and computational modeling analysis (human)
(Fig. 3A). Murine and human BCL-3 share 79% sequence
identity at the protein level, which readily facilitates the
alignment of human and mouse proteins. This compara-
tive analysis of the three models revealed a clear overlap in
the amino acids of ANK6 and ANK7 that interact with p50.
Specifically, tyrosine 301 (299 human) and glycine 303
(human 301) in ANK6, and arginine 354 (351 human) in
ANK7 were identified by three of the 4 models including the
peptide array (Fig. 3, A and B). Overall the peptide array data
most closely matches a model proposed by Manavalan et al.
(15) (Model A) which assumes that the BCL-3p50 complex
is DNA bound (Fig. 3A).
Our peptide array experiments also identified two potential
p50 interacting binding regions not identified by the previous
computationalmodels. These sites are comprised of residues in
ANK1 and the N terminus of BCL-3 (Fig. 3, A and B). Of note,
the ANK1 region of BCL-3 has previously been demonstrated
to be required for interaction with p50 (21). Neither of these
two regions of BCL-3 are represented in the available BCL-3
crystal structure, however, the in silico models of BCL-3:p50
homodimers would suggest that they may interact with the
C-terminal region of p50 (15, 20). In addition, we have
recently demonstrated the C-terminal region of p50 and in
particular amino acids 359–361 and 363, to be required for
interaction with BCL-3 (14). This, combined with the pep-
tide data presented here suggests that the N terminus and
ANK1 of BCL-3 may mediate the interaction with the C-ter-
minal region of p50 to promote the formation of a BCL-3p50
homodimer complex.
TheANK1Region of BCL-3 Is Not Conserved across Other IB
Proteins—In mammals the IB family of proteins includes 9
members characterized by the presence of 6 or 7 central ANK
motifs. The ANK motif is a 33-amino acid motif with a high
degree of conservation and that adopts a canonical helix-turn-
helix conformation in which the two -helices are arranged in
an antiparallel fashion with an almost perpendicular outward
projecting -hairpin loop (22). We analyzed the ANK1 region
identified in our peptide array experiments for sequence simi-
larity with the corresponding regions in IB, IB, IB,
IBNS, IB, p100, and p105. Multiple sequence alignment of
IB family proteins was performed and this analysis revealed
that this region is of low similarity across all IB proteins (Fig.
4). These data indicate that this short region of IB proteins is
largely protein specific and may contribute to dimer selective
properties of individual IB proteins.
Generation of a Bcl-3 Mimetic Peptide—We next assessed
whether the short region of theANK1motif of BCL-3 identified
by peptide array possessed any of the inhibitory activity on the
transcription of NF-B target genes. To do this we first gener-
ated a BCL-3-derived peptide (BDP1) spanning both -helices
of ANK1 and the first  sheet of ANK2 of BCL-3. This region
incorporates the p50 interacting residues identified by our pep-
tide array analysis and spans residues 135 to 164 of murine
Bcl-3 (Fig. 5, A–C). This peptide sequence was fused to the
FIGURE 1. A, crystal structure of human BCL-3 ankyrin repeat domain with
-hairpin (pink) and the inner and outer  helices (yellow) indicated. B,
Bcl-3 binds specifically to GST-p50 in a GST pulldown assay. Purified bac-
terial recombinant GST or GST-p50 was incubated with a whole cell lysate
from HEK293T cells transfected with empty vector (Mock) or FLAG-BCL-3
(BCL-3) and affinity purified with GSH-agarose. Pulldown complexes were
immunoblotted with anti-FLAG and anti-GST antibodies. C, peptide arrays
of immobilized overlapping 18-mer peptides, each shifted to the C termi-
nus by 4 amino acids encompassing the entire BCL-3 sequence were gen-
erated. Arrays were probed with GST or GST-p50 and detected by immu-
noblotting with anti-GST antibody. Positive GST-p50 binding to BCL-3
peptides is shown (black spots) and is representative of duplicate arrays.
Peptide identifier numbers are indicated.D, table of BCL-3 peptides 1–109
with corresponding BCL-3 amino acids and the structural region indi-
cated. WB, Western blot.
Bcl-3Mimetic Peptide
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HIV-tat cargo carrying the sequence YGRKKRRQRR, which
mediates the cellular uptake and subsequent nuclear localiza-
tion of fused peptides (23). Initially we assessed the cellular
uptake and subcellular localization of a FITC-labeled BDP1
peptide using flow cytometry and fluorescence microscopy.
RAW 264.7 macrophage cells were incubated with 2 M FITC-
BDP1 for 2 h prior to analysis by flow cytometry. 98% of cells
were FITC positive indicating strong uptake of the peptide as
expected (Fig. 5D). Fluorescence microscopy of HeLa cells
treated with FITC-BDP1 further demonstrated nuclear local-
ization of the peptide (Fig. 5E).
The impact of the BDP1 peptide on the expression of NF-B
target genes was initially assessed using a luciferase-based
reporter assay incorporating the Il23p19 promoter. Il23p19 is a
NF-B target gene and is negatively regulated by BCL-3 (24).
RAW 264.7 macrophage were transfected with the Il23p19
reporter plasmid prior to treatment with the BDP1 (20 M) for
1.5 h prior to stimulationwith LPS (100 ng/ml) for an additional
8 h. Measurement of luciferase activity showed that the BDP1
peptide effectively inhibited LPS-inducible reporter activity
and that this level of inhibition was similar to that observed
following the overexpression of full-length BCL-3 (Fig. 5F).
Together these data identify the BDP1 peptide as amimic of the
inhibitory action of BCL-3 on NF-B target gene expression
following LPS treatment.
BCL-3Mimetic Peptide Inhibits Inflammation in Vivo—Pep-
tide cargo size can effect cellular uptake and cytotoxicity of cell
permeable peptides (25) and so we next sought to further opti-
mize the BDP1 peptide by reducing it in size. A 25-amino acid
BCL-3-derived peptide (BDP2) was generated that consisted of
BCL-3 amino acids 144–158 fused with the HIV tat cargo car-
rying sequence (Fig. 6A). TheBDP2peptidewas tested as before
using the Il23p19 luciferase reporter assay, which demon-
strated that the shorter BDP2 peptide retained inhibitory activ-
ity (Fig. 6B). Peptide treatment did not significantly affect cell
viability at the concentrations used in our studies, although
cytotoxcity was observed using higher concentrations of pep-
tide (LC50  80 M) as measured by the WST-1 cell viability
assay (Fig. 6C). To further assess the BDP2 peptide we next
evaluated the effects of the BDP2 peptide using an in vivomodel
of acute inflammation in the mouse. We employed the carra-
geenan-induced paw edema mouse model that invokes an NF-
B-dependent acute inflammatory response, which peaks6 h
post administration of carrageenan (19, 26). Mice were admin-
istered 0.1, 1, or 10mg/kg of BDP2 via intraperitoneal injection
1 h prior to injection of carrageenan in the foot pad. An addi-
FIGURE 2. The 18-amino acids of BCL-3-derivied peptides of interest were sequentially substitutedwith alanine, probedwith GST-p50, and detected
by immunoblotting with anti-GST antibody. The peptides are numbered in bold as described in the legend to Fig. 1. p50 binding was quantified by
densitometry and calculated as a percentage binding of the parent unsubstituted peptide on the same array. Alanine substitutions that resulted in less than
60% binding are underlined. Corresponding BCL-3 amino acids are labeled above each individual substitution peptide series.
Bcl-3Mimetic Peptide
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tional group of mice received intraperitoneal injection of the
anti-inflammatory steroid dexamethasone (1mg/ml). The con-
trol group received an injection of PBS intraperitoneally.
Inflammationwas assessed bymeasuring paw size (edema) over
a range of time points up to 6 h post-carrageenan administra-
tion. The results of this analysis demonstrated a significant and
dose-dependent inhibition of inflammation in mice receiving
the BDP2 when compared with control mice (Fig. 6D). At the
highest dose of BDP2 (10 mg/kg) the inhibitory effects on cara-
geenan-induced edema were comparable with dexamethasone
(1 mg/ml) treatment.
To further explore the effects of BDP2 in this model of
inflammation we analyzed the expression of the NF-B target
genes Tnf in whole soft tissue from the paws of mice 6 h follow-
ing carageenan treatment. For this analysis we employed a 10
mg/kg dose of BDP2 peptide. Quantitative PCR analysis
revealed a large increase in mRNA for Tnf in the paws of mice
receiving carageenan treatment compared with untreated
mice. This carageenan-induced Tnf expression was signifi-
cantly inhibited by pre-treatment ofmice with BDP2 peptide to
a level comparable with pre-treatment with dexamethasone
(Fig. 6E). Similar data were obtained for Il6, whereas a trend
toward significant inhibition of Ccl2 and Il1b expression by
BDP2 was also apparent (Fig. 6E). These data reveal that the
BDP2 peptide has potent anti-inflammatory activity in vivo that
results in the significant inhibition of the key pro-inflammatory
cytokines Tnf and Il6.
Anti-inflammatory Action of BCL-3 Mimetic Peptide Re-
quires AminoAcids That Interact with p50—Our initial peptide
array experiments identified individual amino acids in the
BDP2 peptide that are critical for interaction with p50 (Fig. 2).
To assess the importance of these same amino acids to the
anti-inflammatory action of the BDP2 peptide we next gener-
ated a peptide in which these 7 amino acids of BDP2 were
mutated (mBDP2) (Fig. 7A). We pre-treated RAW 264.7 cells
with BDP2 and mBDP2 for 2 h prior to stimulation with LPS
before measuring TNF production by ELISA. This analysis
FIGURE 3. A, alignment of the seven ANK repeats of BCL-3 with a schematic
indicating the conserved structural features of the each ANK repeat. Puta-
tive p50-binding residues of murine BCL-3 identified by peptide array
(Array) in Fig. 2 are shaded in black and compared with p50-binding resi-
dues of human Bcl-3 predicted by the three currently available in silico
models (Model A–C (15, 20)). The  hairpin (-), inner helix (1), outer
helix (2), and linker regions of each ankyrin repeat are indicated. B,
human BCL-3 crystal structure with corresponding unique p50-binding
residues determined by peptide array (blue), p50-binding residues pre-
dicted by combined in silico Models A–C (green), and overlapping residues
identified by both methods (red).
FIGURE 4.Similarity indexofANK1-ANK7of theARDofmurine IB family
members, BCL-3, IB, IB, IB, IBNS, p100, and p105. Bcl-3 residues
144–158 are shaded in black and a multiple sequence alignment of this sec-
tion expanded below. Non-homologous/non-similar residues are indicated
by black text onwhite background, conservative residues derived fromablock
of similar residues at agivenpositionareblack text ongraybackground, blocks
of similar residues derived from a single conservative residue at a given posi-
tion arewhite text on black background andweakly similar residues are under-
lined. The consensus sequence was determined using identical and conser-
vative amino acids.
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revealed that the mBDP2 peptide had no effect on TNF pro-
duction following LPS stimulation, whereas BDP2 pre-treat-
ment resulted in a significant inhibition of LPS-induced TNF
production (Fig. 7B). Of note, the cytotoxicity of high BDP2
concentrations was not observed for the mBDP2 peptide sug-
gesting that BDP2 cytotoxicitymay be associatedwith its inhib-
itory effect on NF-B, which is also an important pro-survival
factor (Fig. 7C). To further extend this analysis we repeated the
carageenan-induced edema experiments described above and
pre-treating mice with BDP2 or mBDP2 (10 mg/kg) as before.
This experiment demonstrated that in contrast to the BDP2
peptide themBDP2 peptide fails to inhibit inflammation in vivo
(Fig. 7D). Together these data show that the BDP2 peptide has
potent anti-inflammatory properties that depends on the
amino acids that interact with p50 and that mimicking BCL-3
function may be a viable therapeutic strategy in the treatment
of inflammatory disease.
Discussion
BCL-3 mediates inhibition of p50 homodimer ubiquitina-
tion, leading to the formation of a stable p50BCL-3 repressor
complex bound to the promoters of NF-B target genes (8).
Interaction with p50 is necessary and sufficient for this anti-
inflammatory function of BCL-3 (14). To further investigate the
role of this complex in the regulation of NF-B-mediated gene
transcription we employed a BCL-3 peptomimetic strategy. A
peptide array approach identified short peptides of BCL-3 with
p50 binding activity representing the N terminus, ANK1, ANK6,
and ANK7. Following alanine substitution analysis, critical resi-
dueswithin thesepeptideswere identified.Therewasconsiderable
overlapbetween the individual residues identifiedbypeptide array
and those predicted from computation modeling particularly in
ANK6 and ANK7, further supporting the peptide array as a
method to identify critical p50 binding regions.
FIGURE 5. A, sequences of Bcl-3 peptides 33–40 from the BCL-3 peptide array described in the legend to Fig. 1 with corresponding BCL-3 amino acid
positions indicated. Amino acids 144–158 are underlined and amino acids 135–164 are indicated by bold type. B, BCL-3 crystal structure showing residues
corresponding to BDP1 shaded in blue. C, schematic representation of murine BCL-3 with amino acids 135–164 of BDP1 indicated. D, flow cytometry
analysis of RAW 264.7 following treatment with 2 M-FITC-labeled BDP1 or vehicle control for 2 h. E, immunofluorescence analysis of HeLa cells treated
with 20 M FITC-labeled BDP for 2.5 h. F, RAW 264.7 cells were transiently transfected with the pLucp19 plasmid and BCL-3 expression vector (BCL-3) or
with empty vector (Mock, BDP) for 24 h. Cells were left untreated (Mock and BCL-3) or pre-treated with 20 M peptide as indicated for 1.5 h before
stimulation with 100 ng/ml of LPS. Cells were cultured for an additional 8 h before luciferase activity was measured. The Renilla luciferase expression
vector pRL-TK was used as an internal control to normalize the transfection efficiency across all samples. Il23p19 reporter activity is represented as
fold-increase over untreated cells transfectedwith pLucp19 plasmid and empty vector expression (Mock). Transfections were performed in triplicate per
experiment and data shown are mean  S.D. and are representative of independent experiments. Statistical significance was determined two-way
analysis of variance with Bonferroni post-hoc analysis, p  0.001 (***).
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FIGURE 6. A, schematic representation of the full-length (BDP1) and shortened (BDP2) BCL-3-derived peptide sequences with corresponding murine Bcl-3
amino acid positions indicated. B, RAW 264.7 cells were transiently transfected with the pLucp19 plasmid and Bcl-3 expression vector (Bcl-3) or with empty
vector (Mock and BDP2) for 24 h. Cells were left untreated (Mock and BCL-3) or pre-treated with 20 M BDP2 peptide for 2 h before stimulation with 100
ng/ml of LPS overnight. Transfections were performed in triplicate per experiment and data shown are mean S.D. and representative of independent
experiments. Il23p19 reporter activity was determined as described in the legend to Fig. 5. Statistical significance was determined two-way analysis of
variance with Bonferroni post hoc analysis, p 0.001 (***). C, RAW 264.7 cells were treated with increasing concentrations of BDP2 peptide (0–100 M)
for 6 h and viability was assessed byWST-1 assay. Viability is expressed as a percentage of the control (no peptide) absorbance A450 nm to A630 nm and data
shown aremean S.D. of 3 independent experiments. Peptide concentration is presented on a Log2 scale.D, PBS (Control), BDP2 (0.1, 1, and 10mg/kg),
and 1 mg/kg of Dex were administered intraperitoneally 1 h before edema induction. 2% -carrageenan was administered by subplantar injection into
the hind paw and edema was evaluated as the difference between basal paw volume and paw volume measured at 2, 4, and 6 h following carrageenan
injection. Data shown are mean  S.E. of individual mice. Statistical significance between control and treatment groups was determined by two-way
analysis of variance with Bonferroni post hoc analysis. For clarity only statistical significance at 6 h was graphed. There was no statistical significant
difference (p	 0.05) between control (n 20) and the 0.1 mg/kg of BDP2 group (n 8) at any time point. 1 mg/kg of BDP2 (n 8) was significant at 4
(*) and 6 h (**), 10 mg/kg of BDP2 (n 20) was significant at 2 (***), 4 (***), and 6 (***) h. 1 mg/kg of Dex (n 20) was significant at 2 (**), 4 (***), and 6
(***) h. Not significant (ns), p 0.05 (*), p 0.01 (**), and p 0.001 (***). E, RNA was extracted from paw tissue at 6 h post-carrageenan injection. Tnf,
Il6, Ccl2, and Il1bmRNA levels were determined by real-time PCR. Data are represented as themean S.E. of individual mice; control, BDP2, and Dex (n
5) and untreated (n 4), BDP2 (10 mg/kg) and Dex (1 mg/kg). Statistical significance was determined by one-way analysis of variance with Tukey’s post
hoc analysis, p  0.05 (*), p  0.01 (**).
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Current computational models of BCL-3/p50 are con-
strained by the available crystal structures, which are limited to
the independent crystal structures of DNA bound p50
homodimer and the central ankyrin repeat domain of BCL-3
(15, 20). In both cases the extreme N- and C-terminal regions
are unstructured and so are not represented in either the
resolved structures or in silicomodels. The data from the exper-
iments performed here along with previous studies on the
interaction of BCL-3 and p50 (14, 15, 20) suggests that the
N-terminal domain of BCL-3 most likely interacts with the ex-
treme C terminus of p50.
Our peptide array data have identified amino acids of the
N-terminal and ANK1 domain of BCL-3, which interact with
p50. These data are supported by earlier studies indicating that
the first ANK domain is required for interaction with p50 (21).
Multiple sequence alignment of this region of BCL-3-(144–
158) with the homologous regions of the other IB proteins
identifies it as an area of low sequence similarity between IB
proteins. This region has also been suggested to contribute to
the functional divergence of IB factors and has also been
implicated in BCL-3-mediated survival of activated T and B
cells (27, 28). These previous studies and the data presented
here suggested that this region of BCL-3may contain important
functional activity.
To explore the functional activity of peptides comprising the
144–148 sequence of BCL-3 we utilized the HIV tat cargo car-
rying peptide sequence. Because BCL-3 is a predominantly
nuclear protein that regulatesNF-B activity at gene promoters
we reasoned that the tat peptide sequence was most suited to
delivering the BCL-3-derived peptide to the site of BCL-3 activ-
ity as it rapidly translocates through the plasmamembrane and
accumulates in the nucleus (23). Our initial analyses demon-
strated potent inhibitory activity of the BDP peptide in both
luciferase-based reporter and ELISA-based assays of Toll-like
receptor-induced expression of the Il23 and TNF cytokines,
respectively. Of note, both of these genes have previously been
established as targets of BCL-3 inhibitory activity (8, 16). The
BDP peptide was also a potent inhibitor of cytokine gene
expression and inflammation in vivo. Treatment of mice with
the BDP2 peptide was effective in preventing carageenan-in-
duced cytokine expression and paw edema. By mutating the
amino acids identified as important for peptide interactionwith
p50 we were able to demonstrate that the functional effects of
the BDP peptide, both in vitro and in vivo, were dependent on
interaction with p50.
NF-B regulates the transcription of a number of genes crit-
ical for the inflammatory response and is considered a potential
therapeutic target in a range of human diseases where inflam-
mation plays a role. Hundreds of inhibitors of NF-B activation
have been described but are limited by broad specificity (29).
TheBCL-3-derived peptide described here, throughmimicking
BCL-3 function, represents a novel class of anti-inflammatory
agents that target a nuclear regulatory event in theNF-B path-
way. This BCL-3-derived peptide provides an important proof
of principle that targeting transcriptional regulators of inflam-
mation is a valid strategy for developing novel anti-inflamma-
tory compounds of therapeutic value. The BDP peptide is also a
valuable tool for further research onBCL-3 function and for the
FIGURE 7. A, schematic representation of the BDP1, BDP2, and mutated BDP2 (mBDP2) BCL-3-derived peptide sequences with corresponding murine BCL-3
amino acidpositions indicated andmutationsunderlined.B, RAW264.7 cellswere left untreatedor pre-treated for 2 hwith increasing concentrations (10M-40
M) of either BDP2 or mBDP2 peptide before stimulation with 100 ng/ml of LPS. Supernatants were harvested 4 h after stimulation and the concentration of
TNFwas determined by ELISA. ND, not detected. C, RAW 264.7 cells were treated with increasing concentrations of BDP2 or mBDP2 peptides (0–100M) for
6 h and viability was assessed byWST-1 assay. Viability is expressed as a percentage of the control (no peptide) absorbance A450 nm to A630 nm and data shown
are representative of 3 independent experiments. Peptide concentration is presented on a Log2 scale. D, PBS (Control), BDP2 (10 mg/kg), and mBDP2 (10
mg/kg) were administered intraperitoneally 1 h before edema induction. 2% -carrageenan was administered by subplantar injection into the hind paw, and
edemawas evaluated as the difference betweenbasal paw thickness andpaw thicknessmeasured at 2, 4, and 6h following carrageenan injection. Data shown
are mean  S.E. of individual mice, n  15/group. Statistical significance between control and treatment groups was determined by two-way analysis of
variance with Bonferroni post hoc analysis. NS, not significant and p 0.01 (**).
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development of BCL-3-based therapeutic agents for inflamma-
tory disease.
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Supplementary table 1. The 18 amino acids of the Bcl-3 derived peptides 2, 5, 6, 35, 36, 
75, 78, 80, 85 and  87 were sequentially substituted with alanine. Arrays were probed with 
GST-p50 and detected by immunoblotting with anti-GST antibody. GST-p50 binding was 
quantified by densitometry and represented as a percentage binding of the control parent 
peptide peptides.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Peptide 2 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.268 100 _ 
0.228 85.07463 P 
0.328 122.3881 A 
0.308 114.9254 G 
0.438 163.4328 A 
0.428 159.7015 M 
0.438 163.4328 D 
0.408 152.2388 E 
0.528 197.0149 G 
0.498 185.8209 P 
0.638 238.0597 V 
1.038 387.3134 D 
0.618 230.597 L 
0.158 58.95522 R 
0.448 167.1642 T 
0.148 55.22388 R 
0.578 215.6716 P 
0.058 21.64179 K 
0.458 170.8955 G 
Peptide 5 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.648 100 _ 
0.638 98.45679 R 
0.768 118.5185 T 
0.738 113.8889 R 
0.628 96.91358 P 
0.548 84.5679 K 
0.648 100 G 
0.488 75.30864 T 
0.608 93.82716 P 
0.548 84.5679 G 
0.258 39.81481 A 
0.298 45.98765 A 
0.358 55.24691 L 
0.558 86.11111 P 
0.488 75.30864 L 
0.438 67.59259 R 
0.498 76.85185 K 
0.438 67.59259 R 
1.348 208.0247 P 
Peptide 35 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.858 100 _ 
1.308 70.39828 A 
1.908 102.6911 V 
1.498 80.62433 V 
1.428 76.85684 Q 
1.828 98.38536 N 
1.598 86.00646 N 
1.418 76.31862 I 
1.038 55.86652 A 
1.118 60.17223 A 
0.778 41.87298 V 
0.668 35.95264 Y 
0.988 53.17546 R 
1.468 79.00969 I 
1.508 81.16254 L 
1.418 76.31862 S 
1.458 78.47147 L 
0.908 48.86975 F 
0.168 9.041981 K 
Peptide 6 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.948 100 _ 
1.028 108.4388 K 
0.918 96.83544 G 
0.778 82.06751 T 
0.648 68.35443 P 
0.678 71.51899 G 
0.668 70.46414 A 
0.538 56.75105 A 
0.828 87.34177 L 
0.878 92.61603 P 
0.488 51.47679 L 
0.548 57.80591 R 
0.678 71.51899 K 
0.538 56.75105 R 
0.778 82.06751 P 
0.458 48.31224 L 
0.448 47.25738 R 
0.598 63.08017 P 
0.408 43.03797 A 
 
  
Peptide 36 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.818 100 _ 
1.428 78.54785 N 
1.308 71.94719 N 
1.588 87.34873 I 
1.168 64.24642 A 
1.708 93.94939 A 
1.758 96.69967 V 
1.588 87.34873 Y 
1.788 98.34983 R 
1.898 104.4004 I 
1.738 95.59956 L 
1.478 81.29813 S 
1.218 66.9967 L 
1.378 75.79758 F 
0.798 43.89439 K 
1.578 86.79868 L 
1.378 75.79758 G 
1.188 65.34653 S 
0.518 28.49285 R 
Peptide 75 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.098 100 _ 
0.888 80.87432 V 
0.738 67.21311 N 
0.638 58.10565 A 
0.898 81.78506 Q 
0.888 80.87432 M 
0.628 57.1949 Y 
0.708 64.48087 S 
0.648 59.01639 G 
0.528 48.08743 S 
0.378 34.42623 S 
0.078 7.103825 A 
0.438 39.89071 L 
0.608 55.37341 H 
0.438 39.89071 S 
0.078 7.103825 A 
0.598 54.46266 S 
0.568 51.73042 G 
0.068 6.193078 R 
Peptide 78 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.778 100 _ 
0.838 107.7121 H 
0.818 105.1414 S 
0.698 89.71722 A 
0.728 93.57326 S 
0.958 123.1362 G 
0.768 98.71465 R 
0.678 87.14653 G 
1.188 152.6992 L 
1.118 143.7018 L 
0.798 102.5707 P 
1.178 151.4139 L 
1.148 147.5578 V 
0.258 33.16195 R 
0.818 105.1414 T 
0.918 117.9949 L 
0.868 111.5681 V 
0.218 28.02057 R 
0.648 83.29049 S 
Peptide 80 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.298 100 _ 
0.238 79.86577 L 
0.308 103.3557 P 
0.378 126.8456 L 
0.408 136.9128 V 
0.318 106.7114 R 
0.348 116.7785 T 
0.318 106.7114 L 
0.428 143.6242 V 
0.068 22.81879 R 
0.668 224.1611 S 
0.528 177.1812 G 
0.138 46.30872 A 
0.558 187.2483 D 
0.538 180.5369 S 
0.548 183.8926 G 
0.558 187.2483 L 
0.088 29.5302 K 
0.558 187.2483 N 
  
Peptide 85 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.928 100 _ 
0.688 74.13793 N 
0.858 92.4569 D 
0.638 68.75 T 
0.618 66.59483 P 
0.718 77.37069 L 
0.568 61.2069 M 
0.568 61.2069 V 
0.578 62.28448 A 
0.508 54.74138 R 
0.398 42.88793 S 
0.298 32.11207 R 
0.298 32.11207 R 
0.648 69.82759 V 
0.538 57.97414 I 
0.958 103.2328 D 
0.628 67.67241 I 
0.628 67.67241 L 
0.198 21.33621 R 
Peptide 87 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.928 100 _ 
0.778 83.83621 R 
0.728 78.44828 S 
0.618 66.59483 R 
0.538 57.97414 R 
0.708 76.2931 V 
0.708 76.2931 I 
0.888 95.68966 D 
0.848 91.37931 I 
0.768 82.75862 L 
0.668 71.98276 R 
0.878 94.61207 G 
0.758 81.68103 K 
0.678 73.06034 A 
0.748 80.60345 S 
0.608 65.51724 R 
0.588 63.36207 A 
0.408 43.96552 A 
0.698 75.21552 S 
Pasquale Maffia and Ruaidhrí J. Carmody
Patricia E. Collins, Gianluca Grassia, Amy Colleran, Patrick A. Kiely, Armando Ialenti,
B) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptideκ(NF-
BκMapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor 
doi: 10.1074/jbc.M115.643700 originally published online April 28, 2015
2015, 290:15687-15696.J. Biol. Chem. 
  
 10.1074/jbc.M115.643700Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2015/04/28/M115.643700.DC1.html
  
 http://www.jbc.org/content/290/25/15687.full.html#ref-list-1
This article cites 29 references, 17 of which can be accessed free at
 at G
lasgow
 U
niversity Library on A
pril 21, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
